You searched for: pd l1 expression (Engelska - Kroatiska)

pd-l1 expression
ekspresija pd-l1

orr by tumour pd-l1 expression
orr prema tumorskoj ekspresiji pd-l1

orr (95% ci) by tumour pd-l1 expression level
orr (95% ci) prema razini tumorske ekspresije pd-l1

os benefit was observed regardless of tumour pd-l1 expression level.
korisni učinci na os bili su opaženi neovisno o razini tumorske ekspresije pd-l1.

assessment of pd-l1 status
ocjena pd-l1 statusa

table 8 summarizes results of orr and os by tumour pd-l1 expression.
u tablici 8 sažeto su prikazani rezultati za orr i os prema tumorskoj ekspresiji pd-l1.

in terms of orr, increasing pd-l1 expression was associated with larger orr.
s obzirom na orr, povećana ekspresija pd-l1 bila je povezana s većim orr-om.

however, the role of this biomarker (pd-l1 expression) has not been fully elucidated.
međutim, uloga tog biološkog biljega (ekspresije pd-l1) nije posve razjašnjena.

tumour pd-l1 expression was determined using the pd-l1 ihc 28-8 pharmdx assay.
tumorska ekspresija pd-l1 određivala se uz pomoć testa pd-l1 ihc 28-8 pharmdx.

however, the role of this biomarker (tumour pd-l1 expression) has not been fully elucidated.
međutim, uloga tog biološkog biljega (tumorske ekspresije pd-l1) nije posve razjašnjena.

figure 3: progression-free survival by pd-l1 expression: 5% cutoff (ca209067)
slika 3: preživljenje bez progresije bolesti prema ekspresiji pd-l1: granična vrijednost od 5% (ca209067)

both nivolumab-containing arms demonstrated greater objective response rates than ipilimumab regardless of pd-l1 expression levels.
obje skupine čija je terapija uključivala nivolumab ostvarile su veće stope objektivnog odgovora nego skupina liječena samo ipilimumabom, neovisno o razini ekspresije pd-l1.

among patients with quantifiable tumour pd-l1 expression, the distribution of patients was balanced across the three treatment groups.
bolesnici s mjerljivom tumorskom ekspresijom pd-l1 bili su ravnomjerno raspodijeljeni u sve tri liječene skupine.

assessment according to discrete pd-l1 expression intervals were not included in the prespecified analyses due to the small sample sizes within the intervals.
pd-l1 nije bila uključena u unaprijed specificirane analize zbog male veličine uzoraka unutar tih raspona.

relative to nivolumab monotherapy, an increase in pfs for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression.
u odnosu na monoterapiju nivolumabom, produljenje pfs-a uz liječenje kombinacijom nivolumaba i ipilimumaba ustanovljeno je samo u bolesnika s niskom razinom tumorske ekspresije pd-l1.

quantifiable tumour pd-l1 expression was measured in 79% of patients in the opdivo group and 77% of patients in the docetaxel group.
mjerljiva tumorska ekspresija pd-l1 utvrđena je u 79% bolesnika u skupini koja je primala opdivo i 77% bolesnika u skupini liječenoj docetakselom.

keytruda is specifically for lung tumours that produce a protein known as pd-l1.
lijek keytruda namijenjen je posebno za tumore pluća koji proizvode bjelančevinu pd-l1.

randomisation was stratified by braf and tumour pd-l1 status and best response to prior ipilimumab.
randomizacija je bila stratificirana prema braf i tumorskom pd-l1 statusu te najboljem odgovoru na prethodno liječenje ipilimumabom.

additional prespecified subgroup analyses were conducted to evaluate the efficacy of tumour pd-l1 expression at predefined levels of 1%, 5% and 10%.
provedene su i dodatne unaprijed specificirane analize podskupina radi ocjenjivanja djelotvornosti kod unaprijed utvrđenih razina tumorske ekspresije pd-l1 od 1%, 5% i 10%.

among patients who were evaluable for pd-l1 expression (98%), 82% were pd-l1 positive and 18% were pd-l1 negative.
među bolesnicima u kojih se mogla odrediti ekspresija pd-l1 (98%), njih 82% bilo je pd-l1 pozitivno, a njih 18% pd-l1 negativno.